Study Comparing Repotrectinib and Crizotinib for Advanced ROS1-positive Non-Small Cell Lung Cancer

Inclusion Criteria

• Have a confirmed diagnosis of advanced non-small cell lung cancer (NSCLC).
• Have a specific genetic change in the cancer called ROS1-positive, confirmed by a test.
• Have at least one tumor that can be measured by scans.
• Have not been treated with certain cancer drugs known as tyrosine kinase inhibitors (TKIs) that work on ROS1-positive NSCLC.
• May have had one previous treatment for NSCLC.
• Be in relatively good health, with a performance status score of 2 or less, meaning fully active or able to do light work.

Exclusion Criteria

• Have cancer that has spread to the brain or the membranes surrounding the brain and is causing symptoms.
• Have had another type of cancer that needed treatment in the past two years, except for the skin cancers or completely removed in situ cancers.
• Have other known genetic changes in the tumor that can be targeted by treatments.
• Have significant heart disease that is active or was present in the last six months.

Note: There are additional criteria that may apply.